Physician profile
Carl E Flor
NPI 1154432375
$1,778.47
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $475 · 2021: $506 · 2022: $217.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $449.25 | 2019-2022 | |
| Novo Nordisk INC | $272.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.09 | 2019-2022 | |
| Pfizer INC. | $146.28 | 2019-2021 | |
| Lilly USA, LLC | $98.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $77.82 | 2019-2021 | |
| Amarin Pharma, INC. | $71.98 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.17 | 2019-2021 | |
| Astellas Pharma US INC | $54.42 | 2019-2020 | |
| Gilead Sciences, INC. | $52.43 | 2019-2020 | |
| Amgen INC. | $35.71 | 2019 | |
| Abbvie INC. | $34.16 | 2022 | |
| Mylan Specialty L.P. | $33.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $32.16 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26.28 | 2020-2021 | |
| Eisai INC. | $25.32 | 2021 | |
| Almatica Pharma LLC | $24.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.99 | 2022 | |
| Aytu Biopharma, INC. | $13.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Flor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.